Aquestive Therapeutics’ (AQST) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the stock.

AQST has been the topic of a number of other reports. Piper Sandler began coverage on Aquestive Therapeutics in a research report on Thursday, April 11th. They issued an overweight rating and a $10.00 price target on the stock. JMP Securities raised their target price on Aquestive Therapeutics from $8.00 to $10.00 and gave the company an outperform rating in a research note on Friday, March 15th. Finally, Raymond James began coverage on Aquestive Therapeutics in a research note on Thursday, March 28th. They issued an outperform rating and a $7.00 target price for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Aquestive Therapeutics has an average rating of Buy and a consensus price target of $8.00.

Aquestive Therapeutics Stock Down 10.0 %

Shares of Aquestive Therapeutics stock opened at $3.36 on Tuesday. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23. The stock has a market capitalization of $246.29 million, a P/E ratio of -24.00 and a beta of 2.87. The stock has a 50 day moving average price of $4.20 and a two-hundred day moving average price of $2.85.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Tuesday, March 5th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The company had revenue of $13.21 million during the quarter, compared to analyst estimates of $11.79 million. Sell-side analysts anticipate that Aquestive Therapeutics will post -0.36 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Alexander Mark Schobel sold 25,000 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the completion of the transaction, the insider now directly owns 1,040,371 shares in the company, valued at approximately $5,399,525.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.39% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors have recently modified their holdings of the stock. PFG Investments LLC acquired a new position in shares of Aquestive Therapeutics during the 1st quarter worth about $204,000. Essex Investment Management Co. LLC acquired a new position in shares of Aquestive Therapeutics during the 4th quarter worth about $1,709,000. Jump Financial LLC acquired a new position in shares of Aquestive Therapeutics during the 4th quarter worth about $60,000. Legato Capital Management LLC bought a new position in shares of Aquestive Therapeutics during the 4th quarter valued at about $688,000. Finally, Armistice Capital LLC lifted its holdings in shares of Aquestive Therapeutics by 314.5% during the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock valued at $7,344,000 after purchasing an additional 3,642,000 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.